Published in Ther Drug Monit on January 01, 1982
Thioridazine: resurrection as an antimicrobial agent? Br J Clin Pharmacol (2007) 0.95
Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. Cell Mol Neurobiol (1999) 0.77
Region specific distribution of levomepromazine in the human brain. J Neural Transm (Vienna) (2005) 0.77
A database of mutants and effects of site-directed mutagenesis experiments on G protein-coupled receptors. Proteins (1996) 1.17
Chlorpromazine, methotrimeprazine, and metabolites. Structural changes accompanying the loss of neuroleptic potency by ring sulfoxidation. Mol Pharmacol (1982) 1.16
Plasma level monitoring of antipsychotic drugs. Clinical utility. Clin Pharmacokinet (1986) 0.96
Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther (1977) 0.96
Involvement of prostaglandins and CGRP-dependent sensory afferents in peritoneal irritation-induced visceral pain. Regul Pept (1997) 0.95
Maintenance therapy with a new retard tablet preparation of procainamide. Am Heart J (1976) 0.88
Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol (1986) 0.87
Response heterogeneity of 5-HT3 receptor antagonists in a rat visceral hypersensitivity model. Eur J Pharmacol (1996) 0.86
Pharmacokinetics of methotrimeprazine after single and multiple doses. Clin Pharmacol Ther (1976) 0.86
Reversal by kappa-agonists of peritoneal irritation-induced ileus and visceral pain in rats. Life Sci (1997) 0.85
Fedotozine blocks hypersensitive visceral pain in conscious rats: action at peripheral kappa-opioid receptors. Eur J Pharmacol (1997) 0.85
Phenothiazine drug metabolites: dopamine D2 receptor, alpha 1- and alpha 2-adrenoceptor binding. Eur J Pharmacol (1986) 0.83
Molecular modeling of serotonin, ketanserin, ritanserin and their 5-HT2C receptor interactions. Eur J Pharmacol (1996) 0.83
Molecular dynamics of the 5-HT1a receptor and ligands. Protein Eng (1993) 0.83
Antinociceptive effects of morphine and U-50,488H on vaginal distension in the anesthetized rat. Life Sci (1997) 0.81
Antinociceptive effects of neuropeptide Y and related peptides in mice. Brain Res (1996) 0.81
Molecular structure and dynamics of cis(Z)-and trans(E)-flupenthixol and clopenthixol. Pharm Res (1991) 0.80
A putative model of the dopamine transporter. Brain Res Mol Brain Res (1994) 0.80
Ligand induced conformational states of the 5-HT(1A) receptor. Eur J Pharmacol (2001) 0.80
Salbutamol potentiates the relaxant effects of selective phosphodiesterase inhibitors on guinea pig isolated trachea. Fundam Clin Pharmacol (1996) 0.79
Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci (1988) 0.79
Molecular model of the Escherichia coli Na1/H1 antiporter NhaA. Receptors Channels (2001) 0.78
Influence of the cation on the side-effects of urographic contrast media. Acta Radiol Diagn (Stockh) (1976) 0.78
Binding affinity of levomepromazine and two of its major metabolites of central dopamine and alpha-adrenergic receptors in the rat. Psychopharmacology (Berl) (1981) 0.78
Identification of O-demethylated and ring-hydroxylated metabolites of methotrimeprazine (levomepromazine) in man. Drug Metab Dispos (1982) 0.78
Effect of levomepromazine and metabolites on debrisoquine hydroxylation in the rat. Pharmacol Toxicol (1994) 0.77
Anti-apomorphine effects of phenothiazine drug metabolites. Psychopharmacology (Berl) (1987) 0.77
Metabolism of levomepromazine in man. Eur J Drug Metab Pharmacokinet (1995) 0.77
The discriminative stimulus properties of U50,488 and morphine are not shared by fedotozine. Eur Neuropsychopharmacol (1998) 0.77
The ligand binding site of NPY at the rat Y1 receptor investigated by site-directed mutagenesis and molecular modeling. Mol Cell Endocrinol (1998) 0.77
Molecular modelling of UH-301 and 5-HT(1a) receptor interactions. Protein Eng (1996) 0.77
Differential inhibition by selective phosphodiesterase inhibitors of antigen, LTC4 and histamine-induced contraction of guinea-pig isolated trachea. Pulm Pharmacol (1996) 0.76
Molecular dynamics of NPY Y1 receptor activation. Bioorg Med Chem (1999) 0.76
Pharmaceutical and pharmacokinetic principles in the formulation of a sustained-release procainamide tablet. Pharm Acta Helv (1976) 0.75
Differential effects of fedotozine compared to other kappa agonists on diuresis in rats. J Pharmacol Exp Ther (1996) 0.75
Molecular structure and dynamics of tricyclic antidepressant drugs. Eur Neuropsychopharmacol (1991) 0.75
Molecular structure and dynamics of the four 10-hydroxynortriptyline isomers. Neuropsychopharmacology (1992) 0.75
[Dosage of drugs with regard to their distribution volume and biological half-life]. Tidsskr Nor Laegeforen (1974) 0.75
Identification of nonpolar methotrimeprazine metabolites in plasma and urine by GLC-mass spectrometry. J Pharm Sci (1977) 0.75
GLC determination of methotrimeprazine and its sulfoxide in plasma. J Pharm Sci (1976) 0.75
Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup. Eur J Clin Pharmacol (1977) 0.75
Pharmacokinetic aspects of new antipsychotic drugs. Neuropharmacology (1981) 0.75
Molecular modeling of the endogenous peptide Leu-Ser-Ala-Leu, pindolol, 5-hydroxytryptamine and their interactions with the human 5-hydroxytryptamine1B (5-HT1B) receptor. Receptors Channels (1998) 0.75
[Elimination and late effects of hypnotics]. Tidsskr Nor Laegeforen (1974) 0.75
High-performance liquid chromatographic determination of levomepromazine (methotrimeprazine) and its main metabolites in serum and urine. Ther Drug Monit (1990) 0.75
Pharmacokinetic and pharmacodynamic factors causing variability in response to neuroleptic drugs. Psychopharmacol Ser (1987) 0.75
Anticholinergic and cardiodepressive effects of levomepromazine and two of its metabolites on isolated rat atria. Eur J Pharmacol (1976) 0.75
Plasma and erythrocyte levels of methotrimeprazine and two of its nonpolar metabolites in psychiatric patients. Ther Drug Monit (1982) 0.75
Structure-stability relationships of Gd(III) ion complexes for magnetic resonance imaging. J Med Chem (1991) 0.75
[Accumulation and elimination of benzodiazepines]. Tidsskr Nor Laegeforen (1975) 0.75
The ligand-binding site of buspirone analogues at the 5-HT1A receptor. J Pharm Pharmacol (1997) 0.75
Pharmacokinetics and first-pass metabolism of levomepromazine in the rat. Acta Pharmacol Toxicol (Copenh) (1982) 0.75
Gas chromatographic mass spectrometric identification of O-demethylated and mono-hydroxylated metabolites of levomepromazine in blood from psychiatric patients by selected ion recording with high resolution. Biomed Mass Spectrom (1982) 0.75
Absorption of labelled metrizamide, diatrizoate, inulin and water from cerebrospinal fluid to blood. A pharmacokinetic investigation in cats with normal and impaired renal function. Acta Radiol Suppl (1973) 0.75
Human brain receptors, III. Molecular Model: G protein-coupled receptor. Am J Psychiatry (1994) 0.75
Classification of neuroleptics based on their pharmacokinetics. Clin Neuropharmacol (1986) 0.75
[Dosage of drugs with regard to their distribution volume and biological half-life]. Tidsskr Nor Laegeforen (1974) 0.75
Molecular structure and dynamics of acetylcholine. J Neural Transm Gen Sect (1991) 0.75
Molecular structure and dynamics of serotonin. Brain Res Mol Brain Res (1991) 0.75
Antagonism of presynaptic dopamine receptors by phenothiazine drug metabolites. Life Sci (1990) 0.75
Weight variation of tablets based on small-scale production. Pharm Acta Helv (1969) 0.75
Testing error in the screening of bacitracin producing strains for high yielding mutants. Pharm Acta Helv (1972) 0.75
[Letter: Apparent distribution volume, an ambiguous concept in pharmacokinetics]. Tidsskr Nor Laegeforen (1976) 0.75
Templates and models of monoamine transporter proteins. Curr Med Chem (2011) 0.75
Three-dimensional structure and molecular dynamics of cis(Z)- and trans(E)-chlorprothixene. J Pharm Sci (1991) 0.75
Molecular dynamics of serotonin and ritanserin interacting with the 5-HT2 receptor. Brain Res Mol Brain Res (1992) 0.75
High-performance liquid chromatography of levomepromazine (methotrimeprazine) and its main metabolites. J Chromatogr (1990) 0.75